bluebird bio Acquires Durham, NC, Manufacturing Site for Lentiviral Vector Production

bluebird bio said today it has acquired a manufacturing facility in Durham, NC, from an undisclosed seller for $11.5 million, with the goal of producing lentiviral vectors for the company’s cell and gene  therapies .Those therapies, bluebird said, include the cerebral adrenoleukodystrophy treatment Lenti-D™, as well as LentiGlobin™ for transfusion-dependent β-thalassemia and severe sickle cell disease and multiple myeloma treatments bb2121 and bb21217.bluebird said th